Navigation Links
AMDL Teleconference Available on amdl.com at 5:00 p.m. EDT Today
Date:5/22/2008

TUSTIN, Calif., May 22 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL), (http://www.amdl.com ), a world leader in specialty pharmaceuticals with operations in Shenzhen, Jiangxi and Jilin, China, announced today that it has made available the AMDL executive management comments from its Q1 2008 financial results conference call. The document can be accessed via AMDL's corporate website at http://www.amdl.com. Click on "Investor Relations" then "Recent News."

The posted conference call script outlines prepared remarks AMDL's executive management made covering the Company's financial results for the first quarter of FY2008 and the subsequent question and answers from shareholders.
Highlighted comments from AMDL's CEO Gary Dreher included:

-- We have responded to the U.S. FDA regarding requests for information on

our DR-70(TM) cancer test within the time period required;

-- AMDL's executive management team is committed to increasing shareholder

communications, including formally issuing corporate guidance;

-- We are focused on growing annual sales at a minimum rate of 100 percent

over the next three years.

-- 2007 sales were $15 million and we are on track to at least doubling

sales in 2008;

-- AMDL will leverage its land holdings in China (estimated to be worth

between $15-$21 million) to gain a new credit facility in place by Q3,

2008.

-- We plan to finance continued growth with debt and credit lines. We do

not plan to pursue the same type of 25 percent discounted equity

funding as we've done in previous rounds;

-- AMDL's anti-aging Goodnak product line is enjoying high growth demand

and we anticipate it will be exported to the US and Europe in the

future;

-- AMDL's head of R&D Dr. Andrea Small-Howard has concluded that the HPV

Test Kit licensed by the Company for distribution in China, Hong Kong,

Taiwan, Singapore, Malaysia, Thailand, Cambodia and Vietnam has

numerous advantages over other test kits for HPV and can become a major

product for the Company.

About AMDL:

AMDL, Inc. is a global specialty pharmaceutical company. The company is headquartered in Tustin, California with operations in Shenzhen, Jiangxi, and Jilin, China. Along with its subsidiary Jade Pharmaceutical Inc. (JPI), AMDL is devoted to the research, development, manufacture, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products currently in China. The company employs approximately 320 people in the U.S. and China. More information about AMDL and its products can be obtained at http://www.amdl.com .

About Jade Pharmaceutical:

JPI has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiaries, Jade currently manufactures large volume injection fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.

IR Contact: Mr. Paul Knopick

Direct: 949.707.5365

Voicemail: 714.505.4460


'/>"/>
SOURCE AMDL, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Kensey Nash Corporation Announces its First Quarter 2008 Earnings Release Date and Teleconference
2. HMS Holdings Corp. Hosts Third Quarter 2007 Financial Teleconference and Presentation
3. Cepheid Schedules Teleconference and Webcast for Third Quarter 2007 Results
4. Onyx Pharmaceuticals Announces Third Quarter 2007 Financial Results Teleconference and Webcast
5. Vermillion to Host Teleconference and Webcast to Discuss Third Quarter 2007 Financial Results on November 12 at 4:30 pm Eastern Time
6. World AIDS Day Teleconference for Media, Including Helen Epstein, Author of the Invisible Cure, and Beatrice Were, Ugandan Womens Rights Advocate
7. Kensey Nash Corporation Announces Its Second Quarter 2008 Earnings Release Date and Teleconference
8. Interactive Teleconference on Inflammatory Bowel Disease for Patients, Caregivers, and Healthcare Professionals
9. American Pacific to Release Financial Results and Hold Fiscal 2008 First Quarter Investor Teleconference
10. Progen Investor Teleconference Dial In Details
11. HMS Holdings Corp. Hosts Fourth Quarter and Full Year 2007 Financial Teleconference and Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... ... February 26, 2017 , ... ODH, Inc.™ announced today it will exhibit ... Sheraton Pentagon City Hotel in Arlington, VA. ODH’s director of medical strategy, Candace Saldarini, ... to improve Medicaid population health management. , ODH will also have an exhibit booth ...
(Date:2/25/2017)... ... February 25, 2017 , ... FCPX users now have the ability to ... Studios. With ProSharpen Color users have total control over sharpening amount, sharpening radius, threshold, ... With color spectrum tools users can visually see the color range effected with ease ...
(Date:2/24/2017)... ... ... Only two months after the official release of The Private Collection – Edition 2017 ... initiated a second print-run of its lavish luxury travel coffee table book. , ... in at more than six kilos, retails at EUR 1,000 per copy and is ...
(Date:2/24/2017)... ... , ... Dr. Ronald E. Hawkins, vice president for academic ... A. Bell, DO, MBA, HPF, FACOEP-dist., FACEP, as the new dean of ... comes to Liberty from the Ohio University Heritage College of Osteopathic Medicine (OU-HCOM), ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... ... and hearing disabilities, it is so critically important that we all are aware ... That is why Mediaplanet is proud to announce the launch of its newest ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... ITL Limited, ( ASX : ITD ), une société de ... excellents résultats semestriels clos le 31 décembre 2016 par ... « Résultats et mise à jour sur la croissance biomédicale ... Faits marquants Bénéfice ... hausse de 104 %) Bénéfice par action ...
(Date:2/24/2017)... 23, 2017 Non-alcoholic steatohepataitis (NASH) ... various drugs being developed for the treatment ... drugs that are in various phases of ... focuses on novel pharmacologic drugs & regenerative ... therapies, recombinant proteins and RNA-based therapeutics, but ...
(Date:2/24/2017)... Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., an oncology ... it has acquired exclusive worldwide rights to develop, ... HDAC inhibitor targeting hematological and solid tumors. ... 1 and 2 clinical trials of Abexinostat in ... have already been completed, demonstrating that Abexinostat is ...
Breaking Medicine Technology: